Solectron Corporation
NYSE : SLR

Solectron Corporation

August 30, 2005 08:54 ET

Solectron and Insulet Corporation Partner to Expand the Reach of Intensive Insulin Therapy; Insulet Pairs with Solectron for Design and Manufacturing Services

MILPITAS, CALIFORNIA--(CCNMatthews - Aug. 30, 2005) - Business Editors/Health/Medical Writers

Solectron Corporation (NYSE:SLR), a leading provider of electronics manufacturing and integrated supply chain services, today announced a partnership with Insulet Corporation to manufacture the OmniPod™ Insulin Management System. The product debuted at the American Association of Diabetes Educators (AADE) 32nd Annual Meeting and Exhibition on Aug. 11, 2005.

Through collaboration, Solectron provided Insulet with RF engineering, PCB layout, mechanical design, PCBA board spins and contract manufacturing services to accelerate the product introduction cycle. This partnership resulted in helping Insulet quickly bring to market advanced technology for insulin-requiring diabetes patients.

Based on insights from diabetes patients, educators and physicians, Insulet created a new solution that integrates the proven healthcare benefits of continuous subcutaneous insulin infusion (CSII) therapy with blood glucose monitoring technology in a safe, convenient and discreet two-part system. This system eliminates the need for daily insulin injections, does not require people with diabetes to be tethered to a conventional insulin pump via tubing and is designed to make CSII easier to prescribe, learn and use.

"Through this partnership, we were able to meet Insulet's aggressive introduction schedule and bring to market a great new solution for people with diabetes," said Dave Purvis, executive vice president, chief technical officer, Solectron. "The OmniPod System is a terrific innovation and our entire team was elated to be a part of its development. Through this product, we are helping Insulet let people with diabetes lead a more active lifestyle."

"Solectron brought engineering, stringent medical manufacturing knowledge, materials knowledge and supply chain expertise to our team, and quickly augmented our efforts in a seamless, collaborative manner," said Kevin Schmid, Insulet's Vice President of Manufacturing. "The OmniPod System reflects how a partnership really can be mutually beneficial, not only for the companies involved, but also for our customers."

The OmniPod System features fully programmable CSII with multiple basal rates and bolus dosage options, suggested bolus calculations, safety checks and alarm features. The OmniPod System also incorporates blood glucose monitoring technology. Unlike current insulin pumps, which require users to manage many cumbersome individual components such as insulin reservoirs, infusion sets, tubing, insertion devices and carry a separate blood glucose meter, the OmniPod System features a fully-integrated design containing two components:

- The OmniPod: a small, lightweight, self-adhesive pod that delivers insulin according to pre-programmed personal basal rates and bolus dosages. The OmniPod also features automated cannula insertion for reduced insertion errors and increased consistency and comfort.

- The Personal Diabetes Manager: a wireless, hand-held device that programs the OmniPod with customized insulin delivery instructions, monitors the OmniPod's operation, contains a fully integrated blood glucose meter, and automatically stores patient records.

About Solectron

Solectron (www.solectron.com) provides a full range of worldwide manufacturing and integrated supply chain services to the world's premier high-tech companies. Solectron's offerings include new-product design and introduction services, materials management, product manufacturing, and product warranty and end-of-life support. The company is based in Milpitas, Calif., and had sales from continuing operations of $11.64 billion in fiscal 2004.

About Insulet Corporation

Insulet Corporation, located in Bedford, MA, is an innovative, privately held diabetes management company dedicated to providing superior treatment options and lifelong health benefits to people with diabetes. Insulet employees have extensive experience in the diabetes and medical device industries. Founded in 2000, the company seeks to improve the lives of people with diabetes, and to break down the barriers to CSII therapy, through technology and through communication with healthcare professionals and those personally afflicted.


Contact Information